Tags

Type your tag names separated by a space and hit enter

Oral contraceptives and neoplasia of the uterine corpus.
Contraception. 1991 Jun; 43(6):557-79.C

Abstract

Effects of oral contraception on neoplasia of the uterine corpus are reviewed on the basis of epidemiologic studies reported to date. A duration-related protective effect against endometrial cancer occurs from use of combined oral contraceptives, those in which each active pill contains both estrogen and progestogen. The risk before age 60 years is reduced by about 38% with two years of use; use of combined OCs for 4, 8, and 12 years, respectively, confers an estimated 51%, 64%, and 70% reduction in endometrial cancer risk. The protective effect appears not to be diminished by discontinued use, even 15 or more years after stopping. Whether protection continues throughout the entire postmenopausal period, even in the presence of long-term hormone replacement therapy, remains to be seen. Use of combined OCs may protect against uterine leiomyomas ("fibroids"), but the evidence is not conclusive. The few findings about effects of oral contraception on the risk of adenomatous hyperplasia are of uncertain validity. Only one study, with few patients, has considered oral contraception in relation to uterine sarcomas.

Authors+Show Affiliations

Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814.

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

1868733

Citation

Schlesselman, J J.. "Oral Contraceptives and Neoplasia of the Uterine Corpus." Contraception, vol. 43, no. 6, 1991, pp. 557-79.
Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception. 1991;43(6):557-79.
Schlesselman, J. J. (1991). Oral contraceptives and neoplasia of the uterine corpus. Contraception, 43(6), 557-79.
Schlesselman JJ. Oral Contraceptives and Neoplasia of the Uterine Corpus. Contraception. 1991;43(6):557-79. PubMed PMID: 1868733.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral contraceptives and neoplasia of the uterine corpus. A1 - Schlesselman,J J, PY - 1991/6/1/pubmed PY - 1991/6/1/medline PY - 1991/6/1/entrez KW - Age Distribution KW - Age Factors KW - Biology KW - Body Weight KW - Cancer KW - Contraception KW - Contraception Termination KW - Contraceptive Methods--side effects KW - Demographic Factors KW - Diseases KW - Endocrine System KW - Endometrial Cancer KW - Epidemiologic Methods KW - Estrogens--administraction and dosage KW - Family Planning KW - Fertility KW - Fertility Measurements KW - Genitalia KW - Genitalia, Female KW - Histology KW - Hormones KW - Incidence KW - Measurement KW - Neoplasms KW - Oral Contraceptives--side effects KW - Parity KW - Physiology KW - Population KW - Population Characteristics KW - Population Dynamics KW - Research Methodology KW - Risk Factors KW - Urogenital System KW - Uterine Effects KW - Uterus SP - 557 EP - 79 JF - Contraception JO - Contraception VL - 43 IS - 6 N2 - Effects of oral contraception on neoplasia of the uterine corpus are reviewed on the basis of epidemiologic studies reported to date. A duration-related protective effect against endometrial cancer occurs from use of combined oral contraceptives, those in which each active pill contains both estrogen and progestogen. The risk before age 60 years is reduced by about 38% with two years of use; use of combined OCs for 4, 8, and 12 years, respectively, confers an estimated 51%, 64%, and 70% reduction in endometrial cancer risk. The protective effect appears not to be diminished by discontinued use, even 15 or more years after stopping. Whether protection continues throughout the entire postmenopausal period, even in the presence of long-term hormone replacement therapy, remains to be seen. Use of combined OCs may protect against uterine leiomyomas ("fibroids"), but the evidence is not conclusive. The few findings about effects of oral contraception on the risk of adenomatous hyperplasia are of uncertain validity. Only one study, with few patients, has considered oral contraception in relation to uterine sarcomas. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/1868733/Oral_contraceptives_and_neoplasia_of_the_uterine_corpus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010-7824(91)90004-Y DB - PRIME DP - Unbound Medicine ER -